



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

StockExchange-NSE letters/MM:SA:681

August 11, 2017

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E) Mumbai 400 051

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub : Outcome of the Meeting of the Board of Directors - Unaudited Financial Results for the quarter ended on June 30, 2017.

In compliance with Regulation 30(2) and Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular no. CIR/CFD/CMD/4/2015 dated September 09, 2015, enclosed please find unaudited financial results for the quarter ended on June 30, 2017 accompanied by limited review report. These financial results have been approved and taken on record by the Board of Directors at its meeting held today, which commenced at 11.45 a.m. and concluded at 1.20 p.m.

We request you to take the above on record.

Thanking you,

Yours faithfully,

for J. B. Chemicals & Pharmaceuticals Limited

M. C. Mehta
Company Secretary and Vice President - Compliance

Encl: As above



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2017

(Rs. In lakhs)

Sl.No.	PART I - Particulars	Quarter ended		Year ended	
		6/30/2017	3/31/2017	6/30/2016	3/31/2017
		Unaudited	Audited	Unaudited	Audited
1	Revenue from Operations	28,383.78	30,626.19	31,428.76	119,869.42
2	Other Income	927.18	1,276.27	1,096.72	4,589.03
3	Total Income (1+2)	29,310.96	31,902.46	32,525.48	124,458.45
4	Expenses				
a.	Cost of materials consumed	8,818.82	9,131.39	9,555.32	36,709.36
b.	Purchases of stock-in-trade	2,436.92	2,857.52	2,135.01	9,624.47
c.	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(134.24)	(663.24)	(174.06)	(1,805.26)
d.	Employees benefits expense	5,582.17	4,989.62	4,620.50	18,786.11
e.	Finance Costs	79.12	(24.05)	77.88	500.13
f.	Depreciation and amortization expense	1,432.84	1,240.46	1,131.67	4,626.42
g.	Other Expenses	8,573.34	9,623.41	8,370.83	34,338.86
	Total Expenses (4)	26,788.97	27,155.11	25,717.15	102,780.09
5	Profit before Tax (3-4)	2,521.99	4,747.35	6,808.33	21,678.36
6	Tax expenses	485.26	532.44	1,822.83	4,381.90
7	Net Profit/(Loss) after Tax and non controlling Interest (5-6)	2,036.73	4,214.91	4,985.50	17,296.46
8	Other Comprehensive Income (net of Tax)	(67.61)	(246.21)	(8.07)	(270.43)
9	Total Comprehensive Income after Tax (7+8)	1,969.12	3,968.70	4,977.43	17,026.03
10	(1) Earning per share(EPS) (of Rs. 2/- each not annualised)				
	(1) Basic	2.32	4.68	5.88	20.07
	(2) Diluted	2.32	4.68	5.88	20.07

NOTES

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on August 11, 2017.
- The sales in the domestic market were impacted as stockists scaled down their purchases in anticipation of introduction of GST due to probable financial impact associated with the pre-GST inventory. De-growth in profit was caused by lower sales and nature of the costs which are mainly fixed. The other factors that affected the profit were appreciation of Rupee against US \$ and higher manpower cost due to increase in domestic field force by over 600 people during last quarter of the previous year. However, this investment in manpower is expected to bring additional sales going forward.
- The Company has completed the buy-back of 12,50,000 equity shares of Rs. 2 each on July 25, 2017. Post buy-back, the share capital of the Company is Rs. 16,71,39,950 divided into 8,35,69,975 equity shares of Rs. 2 each.
- The auditors have carried out limited review of the financial results for the quarter ended on June 30, 2017 and their report does not contain any qualification.
- The Company has one reportable segment viz. Pharmaceuticals.
- The figures for the quarter ended on March 31, 2017 are the balancing figures between audited figures in respect of the year ended on March 31, 2017 and published year-to-date figures up to December 31, 2016.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.


J.B. Mody

Chairman & Managing Director

Place : Mumbai

Date : 11/08/2017

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
@ info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380

LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY STANDALONE FINANCIAL RESULTS

To

The Board of Directors of

J. B. Chemicals and Pharmaceuticals Limited

We have reviewed the accompanying Statement of unaudited financial results of **J. B. Chemicals and Pharmaceuticals Limited** ('the Company'), for the quarter ended June 30, 2017 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

Management's responsibility for the Statement

The Statement is the responsibility of the Company's Management and has been approved by the Board of Directors.

Auditor's responsibility

Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE)-2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For J. K. Shah & Co.

Chartered Accountants

Firm Registration No.: 109606W


J. K. Shah

Partner

Membership No.: 3662



Place: Mumbai

Date: 11th August, 2017



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2017

Sl.No.	PART I - Particulars	(Rs. in lakhs)			
		Quarter ended		Year ended	
		6/30/2017	3/31/2017	6/30/2016	3/31/2017
		Unaudited	Audited	Unaudited	Audited
1	Revenue from Operations	28,383.78	30,626.19	31,428.76	119,869.42
2	Other Income	927.18	1,276.27	1,096.72	4,589.03
3	Total Income (1+2)	29,310.96	31,902.46	32,525.48	124,458.45
4	Expenses				
	a. Cost of materials consumed	8,818.82	9,131.39	9,555.32	36,709.36
	b. Purchases of stock-in-trade	2,436.92	2,857.52	2,135.01	9,624.47
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(134.24)	(663.24)	(174.06)	(1,805.26)
	d. Employees benefits expense	5,582.17	4,989.62	4,620.50	18,786.11
	e. Finance Costs	79.12	(24.05)	77.88	500.13
	f. Depreciation and amortization expense	1,432.84	1,240.46	1,131.67	4,626.42
	g. Other Expenses	8,573.34	9,623.41	8,370.83	34,338.86
	Total Expenses (4)	26,788.97	27,155.11	25,717.15	102,780.09
5	Profit before Tax (3-4)	2,521.99	4,747.35	6,808.33	21,678.36
6	Tax expenses	485.26	532.44	1,822.83	4,381.90
7	Net Profit/(Loss) after Tax and non controlling interest (5-6)	2,036.73	4,214.91	4,985.50	17,296.46
8	Other Comprehensive Income (net of Tax)	(67.61)	(246.21)	(8.07)	(270.43)
9	Total Comprehensive Income after Tax (7+8)	1,969.12	3,968.70	4,977.43	17,026.03
10	(I) Earning per share(EPS) (of Rs. 2/- each not annualised)				
	(1) Basic	2.32	4.68	5.88	20.07
	(2) Diluted	2.32	4.68	5.88	20.07

NOTES

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on August 11, 2017.
- The sales in the domestic market were impacted as stockists scaled down their purchases in anticipation of introduction of GST due to probable financial impact associated with the pre-GST inventory. De-growth in profit was caused by lower sales and nature of the costs which are mainly fixed. The other factors that affected the profit were appreciation of Rupee against US \$ and higher manpower cost due to increase in domestic field force by over 600 people during last quarter of the previous year. However, this investment in manpower is expected to bring additional sales going forward.
- The Company has completed the buy-back of 12,50,000 equity shares of Rs. 2 each on July 25, 2017. Post buy-back, the share capital of the Company is Rs. 16,71,39,950 divided into 8,35,69,975 equity shares of Rs. 2 each.
- The auditors have carried out limited review of the financial results for the quarter ended on June 30, 2017 and their report does not contain any qualification.
- The Company has one reportable segment viz. Pharmaceuticals.
- The figures for the quarter ended on March 31, 2017 are the balancing figures between audited figures in respect of the year ended on March 31, 2017 and published year-to-date figures up to December 31, 2016.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.

Place : Mumbai
Date : 11/08/2017

J. B. Mody



J. B. Mody
J.B. Mody
Chairman & Managing Director

J. B. Mody

Registered Office:

Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:

Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500

+91 22 2431 5331 / 2431 5334

info@jbcpl.com

www.jbcpl.com

CIN: L24390MH1976PLC019380